Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004

International Journal of Cancer

Volumn 126, Issue 1, 2010, Pages 208-216

  Karageorgi, Stalo ^a   Hankinson, Susan E ^a,b   Kraft, Peter ^a   De Vivo, Immaculata ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Endometrial neoplasms; Hormone replacement therapy; Reproductive history

Indexed keywords

ESTROGEN; PROGESTERONE;

ADENOCARCINOMA; ADULT; ARTICLE; BODY MASS; CANCER RISK; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MENOPAUSE; NURSE; POSTMENOPAUSE; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REPRODUCTION; RISK FACTORS;

EID: 73449132941     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24672     Document Type: Article

References (53)

1. Ries Lag MD, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK, eds. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http:// seer.cancer.gov/csr/1975-2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
2. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 2001;943: 296-315.
3. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988; 57:205-12.
4. Albrektsen G, Heuch I, Tretli S, Kvale G. Is the risk of cancer of the corpus uteri reduced by a recent pregnancy? A prospective study of 765,756 Norwegian women. Int J Cancer 1995;61:485-90.
5. Kvale G, Heuch I, Nilssen S. Reproductive factors and cancers of the breast and genital organs-are the different cancer sites similarly affected? Cancer Detect Prev 1991;15:369-77.
6. Kvale G, Heuch I, Nilssen S. Re: "Endometrial cancer and age at last delivery: evidence for an association". Am J Epidemiol 1992;135: 453-5.
7. Kvale G, Heuch I, Ursin G. Reproductive factors and risk of cancer of the uterine corpus: a prospective study. Cancer Res 1988;48:6217-21.
8. McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol 1996;143:1195-202.
9. Hinkula M, Pukkala E, Kyyronen P, Kauppila A. Grand multiparity and incidence of endometrial cancer: a population-based study in Finland. Int J Cancer 2002;98:912-5.
10. Wernli KJ, Ray RM, Gao DL, De Roos AJ, Checkoway H, Thomas DB. Menstrual and reproductive factors in relation to risk of endometrial cancer in Chinese women. Cancer Causes Control 2006;17:949-55.
11. Lambe M, Wuu J, Weiderpass E, Hsieh CC. Childbearing at older age and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:43-9.
12. Brinton LA, Sakoda LC, Lissowska J, Sherman ME, Chatterjee N, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Garcia-Closas M. Reproductive risk factors for endometrial cancer among Polish women. Br J Cancer 2007;96:1450-6.
13. Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lannom L, Hoover RN. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 1992;167:1317-25.
14. Xu WH, Xiang YB, Ruan ZX, Zheng W, Cheng JR, Dai Q, Gao YT, Shu XO. Menstrual and reproductive factors and endometrial cancer risk: results from a population-based case-control study in urban Shanghai. Int J Cancer 2004;108: 613-19.
15. Parslov M, Lidegaard O, Klintorp S, Pedersen B, Jonsson L, Eriksen PS, Ottesen B. Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynecol 2000;182:23-9.
16. Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P, Salmeron-Castro J, Hernandez-Avila M. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res 1999;59:3658-62.
17. Parazzini F, La Vecchia C, Negri E, Fedele L, Balotta F. Reproductive factors and risk of endometrial cancer. Am J Obstet Gynecol 1991;164:522-7.
18. Parazzini F, Negri E, La Vecchia C, Benzi G, Chiaffarino F, Polatti A, Francheschi S. Role of reproductive factors on the risk of endometrial cancer. Int J Cancer 1998;76: 784-6.
19. Lesko SM, Rosenberg L, Kaufman DW, Stolley P, Warshauer ME, Lewis JL, Jr, Shapiro S. Endometrial cancer and age at last delivery: evidence for an association. Am J Epidemiol 1991;133:554-9.
20. Kalandidi A, Tzonou A, Lipworth L, Gamatsi I, Filippa D, Trichopoulos D. A case-control study of endometrial cancer in relation to reproductive, somatometric, and life-style variables. Oncology. 1996;53: 354-9.
21. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005;118(Suppl 12B):64-73.
22. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85: 304-13.
23. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349: 458-61.
24. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-16.
25. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7.
26. Jain MG, Rohan TE, Howe GR. Hormone replacement therapy and endometrial cancer in Ontario. Canada J Clin Epidemiol 2000;53: 385-91.
27. Hill DA, Weiss NS, Beresford SA, Voigt LF, Daling JR, Stanford JL, Self S. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000;183:1456-61.
28. Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids 2000;65:659-64.
29. Newcomb PA, Trentham-Dietz A. Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control 2003;14:195-201.
30. Strom BL, Schinnar R, Weber AL, Bunin G, Berlin JA, Baumgarten M, DeMichele A, Rubin SC, Berlin M, Troxel AB, Rebbeck TR. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 2006; 164:775-86.
31. Doherty JA, Cushing-Haugen KL, Saltzman BS, Voigt LF, Hill DA, Beresford SA, Chen C, Weiss NS. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007;197:139e1-7.
32. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10:253-60.
33. Lacey JV, Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:1724-31.
34. Lacey JV, Jr, Leitzmann MF, Chang SC, Mouw T, Hollenbeck AR, Schatzkin A, Brinton LA. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. Cancer 2007;109: 1303-11.
35. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365:1543-51.
36. Colditz GA, Stampfer MJ, Willett WC, Stason WB, Rosner B, Hennekens CH, Speizer FE. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol 1987;126:319-25.
37. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC. Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1990;1:466-73.
38. Newcomer LM, Newcomb PA, Trentham-Dietz A, Storer BE. Hormonal risk factors for endometrial cancer: modification by cigarette smoking (United States). Cancer Causes Control 2001;12:829-35.
39. Burger HG, Hale GE, Robertson DM, Dennerstein L. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. Hum Reprod Update 2007;13:559-65.
40. Bandini LG, Must A, Naumova EN, Anderson S, Caprio S, Spadano-Gasbarro JI, Dietz WH. Change in leptin, body composition and other hormones around menarche-a visual representation. Acta Paediatr 2008;97:1454-9.
41. Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers-evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 2000;74:357-64.
42. Burger HG, Hale GE, Dennerstein L, Robertson DM. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause 2008; 15:603-12.
43. Madigan MP, Troisi R, Potischman N, Dorgan JF, Brinton LA, Hoover RN. Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women (United States). Cancer Causes Control 1998;9:199-207.
44. Moore JW, Key TJ, Bulbrook RD, Clark GM, Allen DS, Wang DY, Pike MC. Sex hormone binding globulin and risk factors for breast cancer in a population of normal women who had never used exogenous sex hormones. Br J Cancer 1987;56:661-6.
45. Moore JW, Key TJ, Clark GM, Hoare SA, Allen DS, Wang DY. Sex-hormone-binding globulin and breast cancer risk. Anticancer Res 1987;7:1039-47.
46. Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, Peeters PH, Onland-Moret NC, Lahmann PH, Berrino F, Panico S, Larranaga N, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008;15: 485-97.
47. Bernstein L, Pike MC, Ross RK, Judd HL, Brown JB, Henderson BE. Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. J Natl Cancer Inst 1985;74:741-5.
48. Dorgan JF, Reichman ME, Judd JT, Brown C, Longcope C, Schatzkin A, Campbell WS, Franz C, Kahle L, Taylor PR. Relationships of age and reproductive characteristics with plasma estrogens and androgens in premenopausal women. Cancer Epidemiol Biomarkers Prev 1995;4:381-6.
49. Musey VC, Collins DC, Brogan DR, Santos VR, Musey PI, Martino-Saltzman D, Preedy JR. Long term effects of a first pregnancy on the hormonal environment: estrogens and androgens. J Clin Endocrinol Metab 1987;64:111-18.
50. Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology 2003;14:247-50.
51. Katsanis WA, Shields LB, Spinnato JA, Gercel-Taylor C, Taylor DD. Immune recognition of endometrial tumor antigens induced by multiparity. Gynecol Oncol 1998;70:33-9.
52. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-33.
53. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1978;130:448-55.